Research ArticleArticle
Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein
Saki Izumi, Yoshitane Nozaki, Takafumi Komori, Kazuya Maeda, Osamu Takenaka, Kazutomi Kusano, Tsutomu Yoshimura, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition October 2013, 41 (10) 1859-1866; DOI: https://doi.org/10.1124/dmd.113.052290
Saki Izumi
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Yoshitane Nozaki
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Takafumi Komori
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Kazuya Maeda
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Osamu Takenaka
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Kazutomi Kusano
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Tsutomu Yoshimura
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Hiroyuki Kusuhara
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Yuichi Sugiyama
Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan (S.I., Y.N., T.K., O.T., K.K., T.Y.); Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K.M., H.K.); and Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama-shi, Kanagawa, Japan (Y.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Substrate-Dependent Inhibition of OATP1B1
Saki Izumi, Yoshitane Nozaki, Takafumi Komori, Kazuya Maeda, Osamu Takenaka, Kazutomi Kusano, Tsutomu Yoshimura, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition October 1, 2013, 41 (10) 1859-1866; DOI: https://doi.org/10.1124/dmd.113.052290
Research ArticleArticle
Substrate-Dependent Inhibition of OATP1B1
Saki Izumi, Yoshitane Nozaki, Takafumi Komori, Kazuya Maeda, Osamu Takenaka, Kazutomi Kusano, Tsutomu Yoshimura, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition October 1, 2013, 41 (10) 1859-1866; DOI: https://doi.org/10.1124/dmd.113.052290
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement